ZFP36L2 Drives 5–10% CRC Mutations Into Metastasis Switch
Updated
Updated · Nature.com · Aug 5
ZFP36L2 Drives 5–10% CRC Mutations Into Metastasis Switch
1 articles · Updated · Nature.com · Aug 5
Summary
Researchers identified ZFP36L2 as a stress-responsive molecular switch that lets intestinal cells dedifferentiate back into LGR5-positive stem-like states needed for wound repair and colorectal cancer metastatic outgrowth.
In mouse colon injury models, deleting Zfp36l2 reduced stem-cell gene expression, blocked regeneration and worsened recovery, showing the protein is required for stress-induced intestinal repair.
In human CRC organoids and xenografts, ZFP36L2 loss sharply impaired liver and lung metastatic seeding and prevented re-entry into canonical LGR5-positive states, even when some tumors later regrew.
Mechanistically, ZFP36L2 bound AU-rich 3′ UTR stress mRNAs, formed RNA-dependent biomolecular condensates and accelerated stress-transcript decay, effectively shutting off the stress program.
Because ZFP36L2 is mutated in 5–10% of colorectal cancers, the findings link those mutations to poorer outcomes by steering metastases away from canonical stem-like growth and toward heterogeneous non-canonical cell states.
Why do stressed colorectal cancer cells need ZFP36L2 to erase stress signals before they can regain LGR5-positive stemness and grow again?
Could blocking ZFP36L2 stop colorectal metastases—or would it also impair gut repair and drive tumors into stranger, harder-to-treat cell states?
ZFP36L2 as a Prognostic Biomarker and Therapeutic Target in Colorectal Cancer Metastasis
Overview
ZFP36L2 is a key RNA-binding protein that normally helps healthy cells by binding to specific mRNA regions and promoting their degradation, keeping cell growth and inflammation in check. In colorectal cancer, loss-of-function mutations in ZFP36L2 prevent this process, leading to the buildup of pro-inflammatory and cancer-promoting mRNAs. This fuels chronic inflammation and uncontrolled cell growth, making tumors more aggressive and resistant to treatment. When ZFP36L2 is missing, cancer cells can switch to abnormal identities, like neuroendocrine or squamous types, which are harder to treat. Rapidly targeting ZFP36L2 or its pathways can overwhelm cancer cells with stress, causing them to self-destruct, but slow disruption risks creating even more resistant tumors. Understanding and targeting this pathway opens new possibilities for cancer therapy and patient monitoring.